EPISODE · Sep 16, 2025 · 3 MIN
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
from Conference Coverage
Host: Ryan Quigley In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.
Embed this episode
NOW PLAYING
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
0:00
3:15
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Conference Coverage?
This episode is 3 minutes long.
When was this Conference Coverage episode published?
This episode was published on September 16, 2025.
Can I download this Conference Coverage episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!